| abstract |
A purified antibody is disclosed which specifically binds a TRAIL receptor DR5, wherein said antibody: na) has apoptosis-inducing activity in the absence of secondary crosslinking in target cells expressing DR5 in vitro , wherein the apoptosis-inducing activity in vitro is characterized by less than 70% target cell viability at an antibody concentration of 2.5 µg/ml; nb) has tumoricidal activity against tumor cells expressing DR5 in vivo ; and nc) does not bind TRAIL receptor DR4, DcR1, or DcR2. |